Cannabis Rescheduling vs Legalization: Which Path Helps Online Buyers?
Rescheduling changes taxes and research, not consumer legality. Full legalization is the better path for buying cannabis online. Here is how they compare.
The short answer
Moving cannabis from Schedule I to Schedule III changes federal tax rules, research rules, and how federal agencies classify the plant. It does not legalize state medical cannabis programs, does not add insurance coverage, and does not change Veterans Affairs policy or firearm law. DEA proposed the move in May 2024. No final rule had been issued as of late 2025.
when will cannabis be rescheduled
What changes
Federal tax rules
Section 280E of the tax code bars deductions and credits for businesses that traffic in Schedule I or Schedule II substances. Medical cannabis operators pay federal tax on gross income, not net income. Schedule III removes that bar. State-licensed dispensaries could deduct rent, payroll, and inventory costs. Industry analysts put effective federal tax rates for some cannabis retailers above 50 percent under 280E. That number would drop.
Research access
Schedule I researchers need a separate DEA registration. The agency long relied on one licensed grow site at the University of Mississippi for study material. Schedule III removes the Schedule I registration tier and lets DEA-registered manufacturers supply cannabis for research. FDA issued draft guidance in January 2025 on clinical research data for cannabis and cannabis-derived products. Studies on dosing, drug interactions, and condition-specific outcomes become easier to run.
Cannabis Rescheduling Impact on Legality: A Comprehensive Guide
Federal recognition of medical use
Schedule III requires a finding of currently accepted medical use. That finding would place the plant in the same class as dronabinol (Marinol), which is already Schedule III. It could speed FDA review of cannabis-derived drugs.
When Will Cannabis Be Rescheduled: A Comprehensive Guide
Possession penalties
Federal simple possession stays a misdemeanor under 21 U.S.C. 844. The maximum for a first offense is one year in prison and a $1,000 fine. Rescheduling alone does not decriminalize possession.
What does not change
- State medical programs. Federal law still prohibits dispensing a controlled substance without DEA registration. State-licensed dispensaries operate under the Rohrabacher-Farr appropriations rider, first passed in 2014, which blocks the Justice Department from spending funds to stop states from carrying out medical cannabis laws. A rider is not a statute. It must be renewed each year.
- Adult-use programs. The rider covers medical programs only.
- Insurance. Medicare Part D, Medicaid, and private plans cover FDA-approved drugs. FDA has approved Epidiolex, dronabinol, and nabilone. Schedule III status creates no billing code and no coverage mandate.
- Veterans Affairs. VHA Directive 1315 bars VA providers from recommending cannabis or completing state medical forms. Rescheduling does not rewrite that directive.
- Firearm purchases. 18 U.S.C. 922(g)(3) applies to users of any controlled substance. Schedule III is still a controlled substance.
- Workplace and DOT testing. Department of Transportation rules under 49 CFR Part 40 test for marijuana metabolites. Federal contractors follow the Drug-Free Workplace Act.
- Banking. Most state dispensaries hold no DEA registration. Banks still file suspicious activity reports on cannabis accounts.
Where the process stands
HHS recommended Schedule III in August 2023 after an FDA review. DEA published a proposed rule in the Federal Register in May 2024. DEA administrative law judge hearings followed in 2025, with testimony from supporters, opponents, and state attorneys general. A final rule requires DEA publication plus a response to public comments. Court challenges are possible after that.
What to watch
- Whether a final rule keeps cannabis in Schedule III or places it elsewhere.
- Whether Congress renews the medical cannabis appropriations rider.
- Whether VA updates Directive 1315.
- Whether FDA approves more cannabis-derived drugs. That is the only path to insurance coverage.
- Whether 280E relief arrives through the rule or through separate legislation.